Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Stealth Biotherapeutics Inc.

Home Clinical Trial Sponsors and OrganizationsStealth Biotherapeutics Inc.

Stealth Biotherapeutics Inc.

2207 Milford Warren Glen Rd, Bloomsbury, New Jersey, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

53

19 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

33

62.3%

Phase 2

12

22.6%

Phase 3

4

7.5%

Phase 4

2

3.8%

Trial Status Distribution

Active, not recruiting

19

35.9%

Available

1

1.9%

Completed

24

45.3%

Recruiting

5

9.4%

Terminated

3

5.7%

Withdrawn

1

1.9%

Clinical Trials

Trials sponsored by this organization (53)

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

Jul 202648 participants

A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

Jul 202622 participants

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

Active, not recruiting

May 2024313 participants

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

Apr 2022102 participants

Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Apr 2022130 participants

Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Mar 2022130 participants

Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Active, not recruiting

Jan 2022130 participants

Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Active, not recruiting

Jan 2022130 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials53
Approvals
News

Back to Organizations